icon
icon
icon
icon
Upgrade
upgrade
Fosgonimeton, a drug for Alzheimer's disease, failed in clinical trials, and Athira Pharma (ATHA.US) plunged 72% after hours
AInvestWednesday, Sep 4, 2024 2:40 am ET
1min read
ATHA --

On Tuesday, local time, Athira Pharma (ATHA.US) announced disappointing news: its candidate drug fosgonimeton failed to meet the primary endpoint and key secondary endpoints in its 2/3 phase clinical trial for Alzheimer's disease. The result led to a 72% drop in the company's stock price in after-hours trading.

The study, named LIFT-AD, aimed to evaluate fosgonimeton as a potential treatment for mild to moderate Alzheimer's disease. Despite the disappointing results, Dr. Javier San Martin, Athira's chief medical officer, expressed optimism for the future in a statement. He noted that the placebo group in the trial did not show a decline in clinical symptoms, and the shorter duration of the study may have limited its ability to fully demonstrate fosgonimeton's therapeutic potential.

Dr. San Martin further explained: "Nevertheless, we still believe that the positive modulation of the HGF (hepatocyte growth factor) pathway has the potential to improve neuronal health markers and may have a positive impact on slowing the disease process." His words conveyed the company's confidence in the drug's potential, despite the current trial results not supporting its effectiveness as a treatment for Alzheimer's disease.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.